EHA 2024 | Challenges in the diagnosis and treatment of hairy cell leukemia
Enrico Tiacci, MD, University of Perugia, Perugia, Italy, comments on the challenges in diagnosing and treating hairy cell leukemia (HCL). Prof. Tiacci discusses some of the biomarkers that allow for the accurate differential diagnosis of HCL, as mimickers of the disease have a worse prognosis and require a different treatment strategy. He also highlights that HCL is a manageable disease, particularly with the advent of novel therapeutic options, but further investigation is needed to optimize treatment in patients who present with an active infection, making them unfit for chemotherapy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kite/Gilead, Deciphera, Innate Pharma, Roche.
